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Rapid Communication
Thrombinography shows acquired resistance to activated
protein C in patients with lupus anticoagulants
V6ronique Regnault l ,  Suzette B6guin2, DenisWahll-3, Emmanuel de Maistrea, H. Coenraad Henrker2,
Thomas Lecomptel-a
rH6matologie, EA 3452, Universit6 Henri Poincar6, Nancy, France
2Synapse B.V, Cardiovascular Research Inst i tute, University Maastr icht,The Netherlands
3M6decine Interne, and aH6matologie Biologique, CHU de Nancy, France
Summary
In patients with lupus anticoagulants (LA), acquired resistance
to activated protein C (APC) is difficult to demonstrate with
clot-based assays due to the presence of the anticoagulant.
Via the conversion f a fluorogenic substrate (thrombinography),
we monitored the complete process of thrombin formation
and decay and its delimitation by the protein C system in eight
consecutive LA-patients without anticoagulant therapy and
non-carriers of the V Leiden polymorphism.Thrombin genera-
tion was trigered in platelet-poor and platelet-rich plasma by
recalcification in the presence ofa low concentration f tissue
factor.
In 7 out of 8 patients we observed a long lag-time before the
thrombin burst (LA effect) together with a marked inability of
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APC to diminish t e thrombin activity.The lag-phase was how-
ever prolonged to some degree byAPC.The effects were more
outspoken i  the presence of phospholipids from Patients'
platelets han with added phospholipids.
Thrombinography thus demonstrates APC resistance in
LA-patients despite the occurrence of long lag-times (clotting
times). The amount of thrombin activity generated in the
presence ofAPC could be a better indicator of the thrombotic
risk than the moment at which the thrombin burst starts.
Thromb Haemost 2003: 89: 208-12
lntroduction
Lupus anticoagulants (LA) are the so-called antiphospholipid
(auto)antibodies with invitro anticoagulant activity. They delay
the burst of thrombin formation and therefbre the moment at
which clotting occurs. Paradoxically, thrombosis [the antiphos-
pholipid syndrome (APS) (1)1, may develop in patients with
such inhibitory antibodies (2, 3). Biochemical experiments have
shown that these antibodies may interfere with the delimitation
of coagulation by APC (4) [also reviewed in (5)], Significant
association was reported between lupus-associated APS and a
decreased ability of APC to prolong clotting times (6, 7).
Plasma clots when -5 nM of thrombin are fotmed, i.e. at the
start of explosive thrombin generation. At that moment>9570 of
all thrombin is still to be formed (8). Such thrombin is presum-
ably still thrombogenic. Heparins, for example, strongly dimin-
ish the amount of active thrombin formed without signifrcantly
affecting the lag-time of thrombin burst and clot formation (8).
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We monitored the development of thrombin in clotting
plasma via the conversion of a fluorogenic substrate (the throm-
binogram) that allows us to observe both the lagtime (clotting
time) and the burst and decay of thrombin that follows.
Thrombin generation and the formation and action of APC
are cntically dependent upon the composition of the phospho-
lipid surface at which these reactions take place (5). In order to
approach the in vivo conditions, we used the platelets of the
patient as the source of phospholipid. In vivo,APC is formed by
the activation of protein C by the thrombin-thrombomodulin
(TM) complex. We therefore not only investigated the effect of
added (exogenous) APC but also that of natural (endogenous)
APC, the latter formed during thrombin generation in the
presence of added recombinant TM.
Methods
Patients
We studied the 8 consecutive patients without anticoagulant
therapy who were refened to our outpatient clinics between
September 2001 and Jtne 2002 and who were markedly
LA-positive according to the criteria of the Subcommittee on
LA of the International Societv on Thrombosis and Haemostasis
(9); Rosner's indexes using the PTT-LA reagent from Diagnostica
Stago (Asnidres, France) ranged from 35 to 80 (cut-off 15). The
clinical features of the patients are summarized in Table 1.
Genotyping for FV R506Q was performed as previously
described (10). ELISA Asserachrom APA@ lDiagnostica Stago),
which is known to detect antibodies to B2-glycoprotein I,
was used to detect "antiphospholipid" antibodies. A first-gener-
ation assay for sensitivity to APC was performed as originally
described (11) with an automated APTT measurement (Akzo-
Nobel). The sensitivity ratio of a normal pooled plasma was
used to derive a normalized ratio (n-APC-SR) for patients.
Course of thrombin activity during clotting
Tluombinography was carried out according to the principles
described by Hemker et al. (12). Venous blood was collected on
1/10 volume 0.129 M trisodium citrate and centrifuged to obtain
platelet-rich and platelerpoor plasmas (PRP/PPP). Tluombino-
grams were recorded in citrated plasma to which trace amounts
(0.5 pM f.c.) of recombinant human tissue factor (Dade
Behring, Marburg, Germany) were added. We used the fluoro-
genic substrate Z-Gly-Gly-Arg-AMC (Bachem, Bubendorf,
Switzerland) (417 pM f.c.), a plate reading fluorometer
(Fluoroskan Ascent, Thermolabsystems, Helsinki, Finland) and
Table l :Cl inical and laboratoryfeatures of patients.Al l  patients were non-carr iers of the FV Leiden polymorphism.Patient LA1
was studied at two occasions | 0 months apart. SLE: systemic lupus erythematosus; PAPS: primary APS; DVT: deep venous thrombosis;
APL:antiphospholipid antibodies. Platelet count was measured in whole blood.The value of APTT withoutAPC obtained with the
normal pooled plasma was 34 s. N/D: not done; N/A: n-APC-SR expression of the result deemed not applicable.
underlying
disease
plateiet
count
Qoe / L)
thrombotic
event
anti-thrombotic
treatment
Rosnet's
index
APL
ELISA
(units/mL)
A
APTT
-APC
(s)
PC sensitiv
APTT
+APC
lty
n-APC-SR
LAla
SLE
430
none none
80 <5 N/D
LAIb 4J9 58 t4 51 .5 >140 N/A
LA2
B lymphoproliferative
disease
t75 none none 35 <5 45 .1 1 1 1 . 1 0.89
LA3
B Iymphoproliferative
disease
t44 none none 48 758 29.s 54.1 0.66
LA4
B lymphoproliferative
disease
z ) 1 none none OJ 4625 N/D
LA5 PAPS 238 DVT asplrm 40 8 37.0 60.4 0.59
LA6 SLE 204 DVT none 58 1 0 47.7 >140 N/A
LA7 SLE 209 DVT none +o z o l >60 >140 N/A
LA8 SLE 78 none asplfln 64 <5 >140 N/A
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appropriate softwa.re (Synapse, Maastricht, The Netherlands).
The total amount of thrombin activity was assessed as the area
under the curve (i.e. the thrombin potential).
Recombinant human TM was a kind gift of Asahi (Japan)
andAPC was prepared in-house (13). TM was added at 10 nM
and APC at 6;7 and 13.9 nM (f.c.). Thrombin generation was
triggered by adding Ca2* (16.1 mM f. c.). The two normals who
had been previously established to be at the upper and lower
limits of the interindividual variation of thrombin activity
(N = 9) were run in parallel.
Sources of phosphol ipids
PRP (obtained by centrifugation at 190 X g) was adjusted to
150 X 10e platelets/L in all patients but the thrombocytopenic
one (LA8, platelet count in PRP of only 117 x l0q/L). Platelet
procoagulant phospholipid activity was provoked in three ways:
1: by activation during the thrombin generating process, 2:
by freezing and thawing, or 3: by inducing microvesicle fotma-
tion with collagen (Horm, Argene, Varilhes, France) (20 pg/ml.,
15 min, 37" C) and centrifuging at 1500 x g to obtain PPP en-
nched in platelet microvesicles (PPP/PMV).
To PPP centrifuged at 13,000 X g in order to discard micro-
vesicles, synthetic procoagulant phospholipids were added as a
mixture of phosphatidyl-serine (20 mole%o), phosphatidyl-
ethanolamine (20 mole7a) and phosphatidyl-choline (60 mole7o);
(dioleylglycero)phospholipids from Avanti Polar Lipids Inc.
(Coger, Pans, France).
Results
As a rule in the plasma of the patients the burst of thrombin
generation started later (Table 2) and reached alower peak than
in normal plasma. The area under the curve (thrombin potential)
was not decreased however (Fig. 1, right panel).
In normal plasma preparations a decrease in thrombin peak
and thrombin potential was seen upon addition of TM and APC
(Fig. 1, left panel, Table 2). In all patients but one (LA5; Fig. I
and Table 2)TM orAPC hardly diminished these parameters. The
lag-phase of the thrombin burst was prolonged to some degree by
APC indicating that it was less insensitive tothe APC effect han
the other parameters (Fig. 1). Resistance to TM or APC was ob-
served in the presence of phospholipids from the patients' plate-
lets but not necessarily with added phospholipids (PPP) (Table 2).
This stresses the importance of studying these reactions in the
presence of the natural phospholipids of the patient as brought by
their platelets. Patient 1 showed an identical pattern of thrombin
generation when measured ata lO-month interval (Table 2).
The traditional test for APC-sensitivity failed to give inter-
pretable results due to a prolonged APTT in 4 of our patients
(Table 1). The n-APC-SR of patients 3 and 5 fell within
the range of values obtained with patients heterozygous for
V Leiden polymorphism (Fig. 2) and appeared tobe misleading
since the thrombin potentials in the presence of APC of these
2 patients were affected to a lesser extent (Table 2). Conversely
the n-APC-SR of patient LA2 fell close to the median for
non LA, non V-Leiden patients (Fig. 2), but thrombinography
clearly showed APC resistance (Table 2).
Discussion
Our results how that in LA-patients abnormally high thrombin
activity can be detected in an experimental setup approaching
the conditions prevailing invivo, i.e. mrnimally diluted plasma,
natural (platelet) procoagulant phospholipids and the presence
of an active protein C system. In contrast to traditional clotting
times, in our test the course of thrombin-concentration after
clotting are recorded. In PRP of both notmals and patients the
presence ofplatelets induces aresistance to APC that is seen to
a lesser extent with frozen-thawed platelets or platelet micro-
vesicles. The effect of TM seems much less subject o this
phenomenon (results with normals, Table 2). At present we have
no exolanation for this observalion.
Figure  l :
Reoresentative throm-
binograms of patient
LA1 .Thrombinograms
with frozen-thawed
normal (left panel) or
LA-positive (right
panel) platelet-rich
plasma triggered with
0.5 pM tissue factor
and I6 .7  mM CaCl2  in
the absence (closed
symbols) or presence
of l0 nMTM (crosses),
6.7 nM (open circles)
or  13 .9  nM (open
diamonds) APC.
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Table 2: Thrombinography.Thrombin activity was recorded in the absence or presence of an active protein C system. Lag-time
to burst of thrombin generation is only given in i ts absence. As expected i t  is short when procoagulant phospholipids are made
available as soon as the reaction starts (frozen-thawed PRP and PPP/PMV). Inhibition of thrombin activity in the presence of TM or
APC is expressed as percentage of the uninhibited area under the curve.The standard deviat ion in the uninhibited plasma being l3%,
inhibit ions <13% were considered not signif icant (_).The f igures in i tal ics are out of the normal range. PRP = fresh platelet-r ich
l$T:;: :nt"V 
= platelet microvesicles in platelet-poor plasma; PPP = platelet-poor plasma centr i fuged at 13,000 x g. N/D:
Figure 2: Normalized
APC sensitivity ratios.
The original APC
resistance clot-based
test was performed
with plasma of
5l4 patients with
thrombotic events but
with neither oral anti-
coagulant herapy nor
lupus anticoagulant
(grey circles) and with
plasma of 7 out of the
8 study patients (black
circles corresponding
to the 3 patients
for whom the
n-APC-SR was
deemed applicable -
see Table | ). Patients
were grouped accord-
ing to factorV geno-
type ( l  38 hetero-
zygous and 4 homo-
zygous Patients).
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The apparent paradox of prolonged clotting times
accompanying thrombophilia disappears if one assumes that not
the lag-time to thrombin burst but rather the amount of throm-
bin formed in the presence of the APC-system is the parameter
that indicates thrombotic risk. This is in line with the observa-
tioris that no shortening of clotting times is usually seen in most
prothrombotic states and that antithrombotic effect of heparin
is not necessarily accompanied by lengthening of TF-induced
clotting times (14).
The combination of APC resistance and delay of thrombin
burst could be explained by assuming that LA inhibits the acti-
vation of factors V and VIII by (meizo)thrombin aswell as their
inactivation by APC. Both processes occur at the phospholipid
surface and thus may be thought o be influenced by phospho-
lipid-dependent antibodies.
An inhibitory effect on thrombin-induced, TM-dependent
protein C activation has been reported in LA-patients (15). This
seems less likely in the present patients because then thrombin
generation would have been resistant to TM but not to APC.
The degree of inhibition of the APC-effect in our patients is
on the whole much higher than that seen in subjects homo-
zygous for the factorV Leiden polymorphism, where about half
of the activity of the APC-system remains (results to be pub-
lished). This is in keeping with the risk of recunent thrombo-
sis over 6 years reported inclinical settings: LA:69V0 (16), fac-
tor V Leiden 39Vo (11).
Our results uggest that thrombin activity might be a bet-
ter indicator of thrombotic risk than clotting times are. Our
study was not designed, however, to establish conelations
with clinical or laboratory data. Because the cunent method
has been completely automated and allows the parallel meas-
urement of up to 48 samples (see www.thrombin.com) it is
suited for the larger clinical studies that are required for this
purpose. It might also serve to chose and dose antithrombotic
therapy in LA patients, at the present time a very challenging
issue (18, 19).
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